Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Avelumab in Combination With ATR Inhibitor M1774 in Patients With ARID1A-mutated Recurrent Endometrial Cancer Who Have Received Prior Immunotherapy

NCT06518564 is registered in ClinicalTrials.gov with Panagiotis Konstantinopoulos, MD, PhD as lead sponsor.

NCT NCT06518564
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06518564 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Avelumab in Combination With ATR Inhibitor M1774 in Patients With ARID1A-mutated Recurrent Endometrial Cancer Who Have Received Prior Immunotherapy
Lead sponsor
Panagiotis Konstantinopoulos, MD, PhD
Phase
Phase 2
Overall status
Recruiting
Start date
November 14, 2024
Completion date
August 31, 2029
Enrollment
25 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

arid1a gene mutation, endometrial cancer, recurrent endometrial carcinoma